The European Community Advisory Board – ECAB was created in 1997. At the time, patient advisory boards only existed on an ad-hoc basis and were convened by the pharmaceutical companies, a major limitation that ECAB successfully overcame by putting forward an innovative model for the patient community to provide meaningful, independent, and valued input in HIV treatment and prevention research.
EATG, within the remit of the European Community Advisory Board (ECAB), addresses critical scientific questions around HIV drug-development and related co-infections as well as access to treatment in the European region as defined by the World Health Organisation.
ECAB is a high-level scientific platform that brings together civil society, scientific researchers, the pharmaceutical industry and international institutions to address key science and policy issues related to HIV and its main co-infections like hepatitis C or tuberculosis.
ECAB is composed by expert patients and treatment advocates coming from the WHO European region continuously working together to end the epidemic by advancing research on HIV/AIDS, broadening access to treatment, training/mentoring new HIV/AIDS advocates and ensuring that the patient Community is a permanent and highly-recognised voice in the research arena. It is a volunteer, community-based structure, also collaborating actively with national and regional Community Advisory Boards in Europe and other groups sharing the same philosophy in other geographical areas. The majority of ECAB members are living with HIV. ECAB members represent the diverse needs, interests, and concerns of the entire spectrum of the European HIV patient community (women, men, injecting drug users, ethnic minorities, people in detention, vulnerable groups etc.).
ECAB aims to promote the harmonisation of the best available clinical practices, standards of care and access to the latest and best available therapies and diagnostic tools throughout Europe, with a particular regard to Central and Eastern Europe. ECAB members meet regularly with the pharmaceutical industry and researchers to discuss, under confidentiality, the advances in HIV drug development and related co-infections, and access to treatment in the European region.
ECAB ‘s work includes:
- Reviewing clinical trial protocols giving the point of view of PLHIV community
- Promoting best practices procedures and ethics
- Promoting universal access to fair, sustainable, affordable drugs
- Promoting research developments improving the quality of living for PLWHA
Members of the ECAB meet in Brussels on a regular basis (see ECAB calendar of meetings). Meetings are confidential with minutes available to ECAB members only.
ECAB meetings don’t only focus on HIV/AIDS. Thematic ECAB meetings are also organised on important topics such as hepatitis C or tuberculosis as co-infections. The co-infection ECAB meetings discuss clinical development, and expanded use of treatments for people living with HIV who are also infected with extensively drug-resistant and multi drug resistant forms of tuberculosis or hepatitis C.
ECAB Steering Committee
Chair : Giulio Maria Corbelli
Scientific Officer : Giorgio Barbareschi
Steering Committee Members :
- Paul Clift
- Fatih Egelioglu
- Sanja Belak Kovacevic
- Memory Sachikonye
- Alain Volny-Anne
- Luís Mendão (BoD Liaison)
- Andrej Senih (Policy Working Group Liaison)